|By Marketwired .||
|August 6, 2014 06:00 AM EDT||
SCOTTSDALE, AZ -- (Marketwired) -- 08/06/14 -- New Amsterdam Sciences (NAS), an emerging bioscience company focused on treating respiratory illnesses, announced today the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS' lead compound NAS911 as a co-therapeutic for existing influenza antivirals currently available to flu patients. Tamiflu is presently the gold standard for prevention or inhibition of the spread of influenza virus A and B.
Studies were conducted through the Therapeutics Development Services program of the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The goal of the research is to identify and advance the development of a co-therapeutic for existing antivirals for influenza. To date, New Amsterdam Sciences has explored the use of NAS911F in a multitude of different preclinical FDA accepted influenza infection models. Studies conducted by the company through third party facilities has demonstrated that NAS911F is shown to be a more effective treatment candidate than Tamiflu in side-by-side animal model comparison studies with end points of duration of flu, symptoms and other key factors supporting the work. An upcoming planned study for NAS is a co-therapeutic study combining Roche's TamiFlu with NAS's NAS911F with expectations of data demonstrating greater efficacy of TamiFlu combined with NAS911F as a combinatory influenza treatment. "Having the development interest and support from DMID for our flu candidate is extremely promising for our prospect pharma partnerships," said Michael Wilhelm, Director of Strategic Partnering. "This aids in the advancement of the most effective flu treatments currently available or in development." NAS is confident the co-therapeutic candidate will not only be more effective at the first symptom of flu but on severe and late stage flu cases as well. The company has explored seasonal and pandemic strains, observing reductions of morbidity and mortality in all models tested. NAS is currently exploring testing with additional influenza strains, including H7N9. These studies would to further explore the ideal dosing regimen for a clinical trial, as well as defining the mechanism of action of NAS911F in these models. NAS911F is a host-targeted immunomodulatory with a significant breadth and depth of safety and efficacy in the dozens of models tested to date.
"Working with the NIH's Influenza Therapeutics Development Program is a serious boon to the development of New Amsterdam Sciences' novel influenza therapeutic, NAS911F," said Jerry Toepfer, Vice President of NAS. "We anticipate this relationship will be an enormous leverage of time and money for our research, directly leading to our clinical trial objectives."
About the National Institute of Allergy and Infectious Diseases (NIAID)
NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About New Amsterdam Sciences
New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. The company's lead compound is NAS911, which is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, radiation sickness, and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial and government markets, focusing specifically on mass casualty biodefense applications. To complete this mission, the company has cultivated numerous study partnerships with industry and academic leaders, including the Vaccine and Gene Therapy Institute of Florida, the University of Rochester, BARDA, NIH and more. For additional information, please visit www.newamsterdamsciences.com.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2652208
Mar. 26, 2017 11:00 AM EDT Reads: 2,184
Mar. 26, 2017 11:00 AM EDT Reads: 2,582
Mar. 26, 2017 10:45 AM EDT Reads: 609
Mar. 26, 2017 10:30 AM EDT Reads: 1,297
Mar. 26, 2017 10:15 AM EDT Reads: 3,002
Mar. 26, 2017 09:30 AM EDT Reads: 4,293
Mar. 26, 2017 09:15 AM EDT Reads: 1,953
Mar. 26, 2017 09:00 AM EDT Reads: 3,879
Mar. 26, 2017 08:15 AM EDT Reads: 2,993
Mar. 26, 2017 08:15 AM EDT Reads: 2,698
Mar. 26, 2017 08:15 AM EDT Reads: 2,889
Mar. 26, 2017 08:00 AM EDT Reads: 4,175
Mar. 26, 2017 05:15 AM EDT Reads: 6,171
Mar. 26, 2017 03:30 AM EDT Reads: 7,313
Mar. 26, 2017 03:30 AM EDT Reads: 3,880